BIIB022 + paclitaxel + carboplatin

BIIB022 + paclitaxel + carboplatin is a combination regimen under investigation for the treatment of advanced solid tumors. BIIB022 is a non-glycosylated human IgG4 monoclonal antibody that specifically targets the insulin-like growth factor 1 receptor (IGF-1R). It inhibits both IGF-1 and IGF-2 from binding to IGF-1R via an allosteric mechanism, thereby blocking downstream PI3K/Akt signaling involved in tumor cell survival and proliferation. Unlike other anti-IGF-1R antibodies, BIIB022 lacks Fc effector function and does not activate antibody-dependent or complement-dependent cytotoxicity[2][3][5]. Paclitaxel is a microtubule-stabilizing agent that disrupts mitosis, while carboplatin is a platinum-based chemotherapeutic that induces DNA crosslinking and apoptosis. The combination aims to enhance antitumor efficacy by targeting multiple pathways critical for cancer cell growth.